Protective effects of *N*-acetylcysteine on cisplatin-induced oxidative stress and DNA damage in HepG2 cells

FUGEN WANG, SHOURONG LIU, YIQIN SHEN, RANGXIAO ZHUANG, JIANJUN XI, HONGYING FANG, XUWAN PAN, JINGJING SUN and ZHAOBIN CAI

The Xixi Hospital of Hangzhou Affiliated to Zhejiang University of Traditional Chinese Medicine, Hangzhou, Zhejiang 310023, P.R. China

Received March 18, 2014; Accepted September 24, 2014

DOI: 10.3892/etm.2014.2019

Abstract. Hepatocyte injury is a common pathological effect of cisplatin (CDDP) in various solid tumor therapies. Thus, strategies for minimizing CDDP toxicity are of great clinical interest. *N*-acetylcysteine (NAC), a known antioxidant, is often used as an antidote for acetaminophen overdose in the clinic due to its ability to increase the levels of glutathione (GSH). In the present study, the aim was to investigate the protective effects of NAC against CDDP-induced apoptosis in human-derived HepG2 cells. The results showed that upon exposure of the cells to CDDP, oxidative stress was significantly induced. DNA damage caused by CDDP was associated with cell apoptosis. NAC pre-treatment significantly reduced the malondialdehyde (MDA) levels and ameliorated the GSH modulation induced by CDDP. NAC also protected against DNA damage and cell apoptosis. These data suggest the protective role of NAC against hepatocyte apoptosis induced by CDDP was achieved through the inhibition of DNA damage and alterations of the redox status in human derived HepG2 cells. These results indicate that NAC administration may protect against CDDP-induced damage.

Introduction

*N*-acetylcysteine (NAC) is an excellent source of sulfhydryl groups and is rapidly absorbed following an oral dose. The well-known role of NAC is as an antidote to acetaminophen toxicity; it has been used for this purpose for >30 years. It is also widely used to treat chronic obstructive pulmonary disorder, pulmonary fibrosis, and contrast-induced nephropathy. NAC also appears to have beneficial effects in conditions such as liver injury, cancer, heart disease, HIV infection and cigarette smoking. In vitro, NAC that has been deacetylated by cytosolic esterases in cells, causes an increase in the concentration of dissociated cysteine and an increase in glutathione (GSH) synthesis at a concentration of 5 mM. In vivo, NAC is actively transported into hepatocytes and converted into metabolites capable of stimulating GSH synthesis. GSH, a tripeptide synthesized from glutamic acid, cysteine and glycine via GSH synthetase and L-glutamate-cysteine ligase, plays a pivotal physiological role in the maintenance of redox status. During conditions of oxidative stress, GSH is depleted in cells, and its biosynthesis is limited by the rate of cellular cysteine uptake. Effective treatment with NAC provides sufficient cysteine to promote detoxification and directly eliminate reactive oxygen species (ROS). NAC also modulates the inflammatory response through signaling pathways that control pro-inflammatory nuclear factor (NF)-κB activation.

The chemotherapeutic agent cisplatin (CDDP) is a potent drug that has successfully been used clinically to treat cancers of the lungs, testis, ovary, cervix and genitourinary tract. The biological activity of CDDP is founded on the formation of covalent products with nucleic acids that interrupt DNA replication, transcription and ultimately, cell cleavage. However, the clinical use of CDDP in chemotherapy is hampered by its severe side-effects. There is evidence that oxidative stress is involved in the liver damage that occurs following the administration of CDDP. A number of studies have demonstrated that CDDP-induced cell damage is contributed to by several ROS. Thus, the protective effect of free radical scavengers may prevent the generation of ROS and block the downstream cascade that leads to cell apoptosis.

Our previous study in vivo showed that NAC raised the antioxidant capacity of hepatic tissue in rats administered alcohol. However, considering the conspicuous effects of NAC in vivo, the protective roles observed for CDDP have not been completely investigated. Therefore, the objective of the present study was to investigate whether beneficial effects are observed in vitro with NAC when cells are exposed to CDDP. Thus, CDDP was employed as damage inducer, and the protective effects of NAC were evaluated through a cell viability assay, apoptosis assay, single cell gel electrophoresis (SCGE) assay and the measurement of biochemical parameters related to redox status in HepG2 cells.

Correspondence to: Professor Zhaobin Cai, The Xixi Hospital Affiliated to Zhejiang University of Traditional Chinese Medicine, 2 Hengjing Road, Hangzhou, Zhejiang 310023, P.R. China
E-mail: hzsxxyy85463955@126.com

Key words: *N*-acetylcysteine, DNA damage, oxidative stress, cisplatin
Materials and methods

**Chemical products.** NAC (CAS No. 616-91-1) and dimethyl sulfoxide (DMSO, CAS No. 67-68-5) were purchased from Sigma-Aldrich (St. Louis, MO, USA). CDDP (cis-diaminedichloroplatinum(II), CAS No. 15663-27-1) was purchased from Melone Pharmaceutical Co., Ltd. (Dalian, China). All other chemicals were analytical grade products.

**Cell culture and treatments.** HepG2 cells were provided by Keygen Biotech Co., Ltd. (Nanjing, China). The cells were stored in liquid nitrogen. All experiments were performed within the third and fifth passages. Cells were grown in a complete cell culture in Dulbecco's modified Eagle's medium (DMEM; Gibco Life Technologies, Carlsbad, CA, USA) with 10% heat-inactivated fetal bovine serum (FBS; Hangzhou Sijiqing Biological Engineering Materials Co., Ltd., Hangzhou, China) and 1% penicillin/streptomycin antibiotic mixture (Gibco Life Technologies) in culture flasks (25 cm²) in a humidified incubator (Thermo Fisher Scientific, Waltham, MA, USA) with an atmosphere of 95% air and 5% CO₂ at 37°C. For subcultivation, cells were passaged when they reached 80-90% confluence in the flask. The cells were trypsinized, washed with phosphate-buffered saline (PBS; pH 7.4) and centrifuged (450 x g, 5 min). Cell viability was determined by staining the cells with trypan blue.

To evaluate the impact of the CDDP on cell viability, the cells were exposed to CDDP (1.0, 2.0, 4.0, 8.0 μM) for a period of 24, 48, 72 h and then analyzed by 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cells incubated with culture medium alone were used as a negative control. HepG2 cells were pre-treated for 3 h with various concentrations of NAC (50.0, 100.0, 200.0 μM) prior to exposure to CDDP (2.0 μM) for 48 h. Cell lysates were formed with 0.1% sodium dodecyl sulfate solution in PBS for determination of the biochemical parameters. The cell suspensions were incubated for 30 min on ice and centrifuged at 550 x g for 10 min (4°C). Subsequently, the supernatants were used for the assessment of the biochemical parameters associated with redox status. In all experiments, solvent controls were included, and NAC and CDDP were dissolved in DMEM.

**Cell viability assessment.** Cell viability was evaluated biochemically with the MTT assay (17). The HepG2 cells were seeded at ~1x10⁵ cells/ml into the wells of a 96-well plate within the third and fifth passages. Different concentrations of NAC and CDDP were added to each well. Following treatment, the medium was carefully replaced with 200 μl DMEM without FBS for 1 h at 37°C. Then, 20 μl 5 mg/ml MTT was added to each well and the cells were incubated for a further 4 h. The MTT solution was removed and 150 μl DMSO was added to lyse the cells. The components of the wells were mixed thoroughly with shaking until the crystals were completely dissolved. The absorbance at 570 nm was measured using a microenzyme-linked immunosorbent assay (ELISA) reader (model 680; Bio-Rad Laboratories, Hercules, CA, USA). The reduction in viability of the cells was expressed as a percentage compared with the viability of the control group, which was designated a viability of 100%. Each experiment was repeated three times in triplicate samples.

**Cell apoptosis assay.** In order to determine the effects of CDDP on HepG2 cell apoptosis, annexin V/propidium iodide (PI) staining was performed and analysis was conducted by flow cytometry (FACSCalibur; BD Biosciences, San Jose, CA, USA), following the instructions of the annexin V FITC apoptosis detection kit (BD Biosciences). Briefly, cells were harvested, washed twice with precooled PBS and resuspended in 500 μl binding buffer following treatment with different concentrations of CDDP and NAC. Then, the cells were stained with 5 μl annexin V-FITC and 5 μl PI for 15 min at room temperature in the dark. The cell suspension was analyzed by flow cytometry. A blue (488 nm) excitation laser was used for both FITC and PI emission channels. The measured results were analyzed using CellQuest version 3.3 software (BD Biosciences).

**SCGE assay.** The SCGE assay was performed according to the procedure described by Singh et al. (18). Following treatment with different concentrations of CDDP and NAC, HepG2 cells were washed twice with PBS, trypsinized for 3 min, and suspended in 1 ml PBS. Cell suspensions were used for the determination of DNA damage. Frosted glass slides were coated previously with 100 μl normal melting agarose (NMA, 1%) and refrigerated to gel the agarose at 0°C for 5 min. For each slide, 75 μl low melting agarose (LMA, 0.65%) was mixed with 5-10 μl single cell suspension at 37°C. All the slides were covered with coverslips and refrigerated to gel the agarose in an ice box. After ~10 min, the coverslips were removed. Then, the slides were coated with 75 μl LMA (0.65%) and the agarose was solidified. The slides were then placed in a closed box containing freshly prepared cell lysis solution (2.5 M NaCl, 100 mM EDTA, 10 mM Tris HCl, 0.5% sodium Na-lauryl sarcosinate, adjusted to pH 10.0 with NaOH, 1% Triton X-100 and 10% DMSO) at 4°C for 1 h. Alkaline unwinding was carried out for 20 min in a horizontal DYCP-38C electrophoresis chamber (Beijing Liuyi Instrument Factory, Beijing, China), which was filled with freshly precooled alkaline buffer (300 mM NaOH, 1 mM EDTA) and electrophoresis was performed in the same buffer for 20 min at 300 mA, 20 V. The slides were then neutralized three times with a neutralization buffer (0.4 M Tris, pH 7.5) for 5 min. Then, the slides were immersed in methanol for 3 min and stained with GelRed (Biotium Inc., CA, USA).

Thereafter, the slides were covered with coverslips and analyzed immediately. The following steps were carried out in the dark. The SCGE results were examined at a magnification of 200 using a BX51 fluorescence microscope (Olympus Corporation, Tokyo, Japan), which was equipped with an excitation filter at 590 nm. Images of the comets were captured by an Olympus DP50 digital camera. The CASPLab analysis system (http://mailbox.univie.ac.at/christoph.helma/comet/) was employed to measure various comet parameters. The results were expressed as tail length, tail moment and olive tail moment in 100 randomly selected comet cells.

**Measurement of GSH, malondialdehyde (MDA) and superoxide dismutase (SOD).** The GSH level was measured by the addition of 5,5’-dithio-bis(2-nitrobenzoic acid) (DTNB). DTNB, a symmetric aryl disulfide, reacts with thiols to yield a
yellow colored chromophore; this product can be quantified by its maximum absorbance at 412 nm. Concentrations of GSH were determined from a freshly prepared standard curve. The measurements were conducted with a model UV-2550 spectrophotometer (Shimadzu Co., Ltd., Tokyo, Japan). The protein concentrations of the supernatant were determined using a bicinchoninic acid (BCA) protein assay kit (Nanjing Jiancheng Bioengineering Institute, Nanjing, China).

Lipid peroxidation was evaluated by measuring MDA concentrations according to the thiobarbituric acid (TBA) method. This method involved the spectrophotometric measurement of the red color produced during the condensation reaction of MDA with thiobarbituric acid. The reactive products were quantified by the absorbance at 532 nm. MDA concentrations were expressed in terms of nmol/mg protein.

SOD activity was measured using a kit (Nanjing Jiancheng Bioengineering Institute), based on the ability of SOD to inhibit the conversion of WST-1 to a formazan dye by superoxide anions produced from a xanthine-xanthine oxidase system. One unit of SOD activity was defined as the amount that caused a 50% reduction in the absorbance at 450 nm. The amount of SOD was expressed in units of U/mg protein.

**Statistical analysis.** All data analyses were performed with SPSS version 16 software (SPSS, Inc., Chicago, IL, USA). All results are expressed as mean ± standard deviation (SD). Statistical analyses were evaluated using one way analysis of variance followed by Dunnett's test. P<0.05 was considered to indicate a statistically significant result. All experiments were performed in triplicate.

**Results**

**Inhibitory effect of CDDP on HepG2 cell growth.** HepG2 cells were incubated with various concentrations of CDDP for 24, 48 and 72 h. The viability of the cells was determined by MTT assay. The viability of the negative control was designated as 100%, and the viability of each experimental culture was expressed as a percentage compared with the negative control. The results obtained are shown in Fig. 1A. CDDP decreased the survival of the cells in a concentration-dependent manner. Following exposure to CDDP at concentrations of 1.0 µM or higher for 24 h, the cellular viability decreased compared with that of the negative control group (P<0.05). In addition, the viability was markedly reduced following 48 and 72 h of treatment with concentrations of CDDP from 1.0 to 8.0 µM compared with that of the control cells (P<0.01).

Apoptosis induced by CDDP in HepG2 cells was evaluated by flow cytometry. In the flow cytometric study, the early apoptotic and late apoptotic cells were labeled by PI in red or FITC in green. As shown in Fig. 2A, the apoptotic cell population, which was displayed on the scatter plot in red or green or both colors, increased from 26.9 to 63.3% as the concentration of CDDP increased from 1.0 to 8.0 µM for the 48-h treatment. Significant elevations were observed for the apoptotic cell population as the CDDP concentration increased.

**HepG2 cell apoptosis contributes to DNA damage.** The results concerning the impact of treatment with CDDP on DNA stability in HepG2 cells are shown in Table I. The evident DNA damage induced by CDDP, as indicated by the tail length, markedly increased even at a low concentration (1.0 µM). Upon exposure to CDDP, the tail length, tail moment and olive tail moment increased in a concentration-dependent manner in the HepG2 cells compared with control group. DNA damage appeared more frequently in cells treated with higher concentrations of CDDP than in cells treated with lower ones. Marked increases were observed in tail length, tail moment and olive tail moment at higher concentrations compared with the control and lower concentrations.

**Oxidative stress damage is induced by CDDP in HepG2 cells.** To evaluate the effects of CDDP on oxidative stress damage in HepG2 cells, the contents of MDA and GSH were determined, as well as the activity of SOD. As shown in Fig. 3, different concentrations of CDDP led to significant (P<0.05) reductions of GSH content and SOD activity compared with that in the control group. The levels of GSH and SOD activity were inversely associated with the concentration of CDDP. When the cells were treated with various concentrations of CDDP (1-8 µM) for 48 h, the MDA content increased from 1.9 to
4.9 nmol/mg protein. These results suggest that CDDP induces oxidative damage in HepG2 cells.

NAC protects HepG2 cells against CDDP-induced growth suppression. Following pretreatment of the HepG2 cells for 3 h with various concentrations of NAC prior to exposure to CDDP, the cell viability was determined by an MTT assay. The results are presented in Fig. 1B. They show that NAC was able to attenuate the growth suppression of HepG2 cells induced by CDDP. The survival rate of the cells that were pre-treated with NAC was higher than that of cells treated with CDDP alone. However, the viability of cells was not affected by a low concentration of NAC. Following pretreatment of the cells with 50, 100 and 200 µM of NAC, the cellular viability increased by 5.1, 16.5 and 23.2%, respectively, compared with that in the cells that were not pretreated with NAC.

The apoptotic rate of HepG2 cells, determined by staining with annexin V-FITC/PI and flow cytometric analysis is shown in Fig. 2B. The apoptotic rate was 39.2% in cells treated with 2 µM CDDP for 48 h. Following pretreatment with different concentrations of NAC (50, 100 and 200 µM), the apoptotic rates reduced to 35.7, 29.8 and 24.6%, respectively. These results indicate that NAC protected apoptosis in a concentration-dependent manner.

Table I. Results of the single cell gel electrophoresis assay after exposure of cultured HepG2 cells to cisplatin for 48 h.

| Concentration (µM) | Tail length | Tail moment | Olive tail moment |
|-------------------|-------------|-------------|------------------|
| 0                 | 5.16±1.03   | 0.43±0.13   | 0.57±0.19        |
| 1                 | 13.97±2.11* | 2.55±0.27*  | 2.03±0.36*       |
| 2                 | 19.81±2.73* | 3.82±0.39*  | 3.15±0.42*       |
| 4                 | 34.94±4.28* | 6.29±0.52*  | 5.19±0.53*       |
| 8                 | 60.15±6.46* | 11.73±1.04* | 9.61±0.89*       |

Data are expressed as the mean ± SD. One hundred nucleoids were analyzed per treatment. *P<0.01 vs. the control (0 µM) group.

The GSH and MDA concentrations and SOD activity in the cells are presented in Table II. The results show that CDDP (1 µM) caused significant reductions of the cellular levels of GSH and SOD compared with those in the control. Pretreatment of the cells with NAC for 3 h restored the GSH and SOD levels in a concentration-dependent manner. Exposure of the cells to CDDP resulted in a significant increase in the formation of MDA, which was attenuated when the cultures were supplemented with NAC.

Discussion

CDDP, an alkylating agent used for the treatment of various solid tumors, is a known inducer of DNA damage. Thus, strategies for minimizing CDDP toxicity are of clinical interest. In the present study, the aim was to investigate the protective role of NAC against CDDP-induced injury in cultured HepG2 cells. The results demonstrated that CDDP inhibited cell growth, in addition to inducing cell apoptosis and DNA double-strand breaks. NAC was shown to ameliorate CDDP-induced DNA damage and oxidative stress in the HepG2 cells.
In the present study, treatment of the cells with 1 µM CDDP resulted in a significant reduction of cell viability. CDDP exerts cytotoxicity by its ability to form complexes with nucleic acids when ligand dissociation from CDDP occurs, leaving a reactive complex that interacts with deoxyribonucleic acid. Subsequently, CDDP causes inter- and intra-strand crosslinks, probably between N7 and O6 of the adjacent guanine molecules, which results in local denaturing of the DNA chain (19,20). This eventually leads to cellular death via apoptotic or non-apoptotic pathways. The DNA damage induced by CDDP is revealed by the SCGE data in the present study. A bigger DNA tail area and a longer DNA tail length compared with those of the control group were identified following the exposure of the HepG2 cells to CDDP. A recent study also reported an increase of comet formation following the treatment of HepG2 cells with platinum compounds at similar concentrations to those of CDDP used in the present study (21). Pretreatment with NAC was able to reduce the DNA injury that was observed in the CDDP group. NAC significantly decreased the cytotoxicity of CDDP due to a protective effect against DNA damage. When the cells were exposed to NAC, the apoptotic and necrotic cell populations

Figure 3. Impact on GSH, MDA and SOD levels in HepG2 cells of exposure to different concentrations of CDDP (1, 2, 4 and 8 µM) for 48 h. (A) GSH levels, (B) SOD activity and (C) MDA levels following the exposure of cultured cells to CDDP. Bars represent the means ± SD of results obtained with three independent cultures per experimental point. GSH, MDA and SOD levels were determined as described in Materials and methods. *P<0.05, vs. the control group, as determined by one way analysis of variance and Dunnett's test. GSH, glutathione; MDA, malondialdehyde; SOD, superoxide dismutase; CDDP, cisplatin.

Figure 4. Effect on DNA damage in HepG2 cells of pretreatment with different concentrations of NAC for 3 h prior to exposure to 2 µM CDDP. (A) Tail lengths, (B) tail moments and (C) olive tail moments of cells pre-treated with different concentrations of NAC. Bars represent the means ± SD. Two slides were prepared and 100 cells were analyzed for comet formation on each. *P<0.05, vs. the CDDP group, as determined by one way analysis of variance and Dunnett's test. NAC, N-acetylcysteine; CDDP, cisplatin.
were clearly reduced. Also, in this experiment, a clear concentration-dependent effect was observed. Apoptosis of cells is closely associated with DNA damage. Serpeloni et al have previously shown that lutein protects against CDDP-induced DNA damage in HepG2 cells and increases the survival rate of the cells (21).

Mistry et al (22) hypothesized that the detachment of the chlorines from CDDP, resulting in the platinum becoming positively charged, would attract the electronegative sulfur moiety of GSH. GSH-CDDP conjugates have been isolated from cells treated with CDDP and from the serum of CDDP-treated rats (23). In the present study, it was observed that NAC reduced CDDP-induced cell apoptosis. NAC, as a precursor of GSH, is one of the most important low molecular weight antioxidants in vivo. It has been suggested that NAC may block the CDDP-dependent oxidation of intracellular GSH (24,25). The increased concentration of GSH is likely to have attenuated the accumulative DNA damage caused by platinum in the HepG2 cells.

Oxidative stress is involved in the toxicities of CDDP. A number of studies have demonstrated the contribution of several ROS in CDDP-induced cell damage (26,27).

For a clearer elucidation of the possible protective properties of NAC, a number of biochemical components associated with the redox status of cells were tested. SOD and GSH are important in the antioxidant defense system, while MDA is regarded as a major marker of lipid peroxidation in tissue. Lipid peroxidation is a consequence of impaired activities of antioxidant enzymes and GSH. GSH, which is a tripeptide, acts as a key ROS scavenger to protect cells in the liver against oxidative stress, and its depletion in hepatic cells could endanger the antioxidant defense system, leading to the accumulation of ROS (28). The present study shows that the GSH content of the HepG2 cells was reduced following exposure to CDDP. The results indicate that CDDP may induce lipid peroxidation products (LPO) by exhausting GSH, leading to the formation of pro-mutagenic exocyclic DNA adducts. The data in the present study regarding markers associated with oxidative stress in the CDDP-treated cells are concordant with the findings of a previous study (29). NAC exhibits antioxidative properties through increasing the concentrations of GSH in cells.

SOD, a scavenger of superoxide, is the most important protective enzyme that provides the first line of enzymatic antioxidant defense against oxidative stress in various organs and tissues (30-32), including the liver. It provides protective effects against oxygen free radicals as it catalyzes the removal of the superoxide radical (O$_2^-$), which damages membranes and biological structures. In the present study, it was found that CDDP significantly decreased the SOD level in HepG2 cells in a concentration-dependent manner. Exposure to CDDP at 1-8 µM for 48 h resulted in a significant reduction of SOD activity, whereas NAC pre-treatment partially reversed this effect.

SOD activity and MDA concentration are usually measured together. MDA is one of the end-products of membrane lipid peroxidation (33). It has been postulated that the mechanism of peroxidation involves the formation of prostaglandin-like endoperoxides from polyunsaturated fatty acids that have two or more double bonds (34). Therefore, in the present study, the MDA concentration was determined as another marker of oxidative damage. The MDA level significantly increased compared with that of control group when the cells were treated with various concentrations of CDDP. This result indicates that lipid peroxidation products were produced as well as DNA damage in the cells. Pretreatment of the cells with NAC for 3 h prior to exposure to 2 µM CDDP, resulted in the MDA levels being reduced.

A reduction or loss of antioxidant enzyme activity in HepG2 cells may result in oxidative stress and induce lipid peroxidation, DNA damage, and cell injury, and subsequent cell death. Leonardo et al (35) demonstrated that PC12 cells treated with CDDP exhibited an increased generation of ROS, which may be one of the main mechanisms by which CDDP exerts DNA genotoxicity. In CDDP-induced renal damage, the increased production of ROS can lead to an enhancement in the expression of proinflammatory mediators, which could intensify the cytotoxic effects (36). In a previous study it was found that the exposure of cells to 2,4,5,2',4',5'-hexachlorobiphenyl (PCB153) decreased SOD activity and the concentration of MDA and increased cell apoptosis, and that NAC pretreatment had a protective effect as it significantly reduced the cell apoptosis (37). In the present study, increased MDA levels and reduced GSH levels and SOD activity were observed in association with CDDP-induced cytotoxicity. The imbalance of the intracellular antioxidant/oxidant system exacerbated HepG2 cell apoptosis. NAC treatment was able to ameliorate the oxidative stress and cytotoxicity.

In summary, the results of the present study suggest that CDDP induces pronounced oxidative stress in HepG2 cells that is associated with DNA damage, and that supplementation with the antioxidant NAC may protect against these adverse

### Table II. Results of pre-treatment with NAC for 3 h prior to incubation with CDDP (2 µM) in HepG2 cells.

| NAC concentration (µM) | GSH (nmol/mg protein) | SOD (U/mg protein) | MDA (nmol/mg protein) |
|------------------------|-----------------------|---------------------|-----------------------|
| 0                      | 34.82±2.74            | 97.92±8.58          | 2.87±0.33             |
| 50                     | 39.14±2.91            | 112.46±9.73         | 2.42±0.31             |
| 100                    | 42.27±3.17            | 119.32±9.52         | 2.03±0.27             |
| 200                    | 46.38±3.29            | 126.75±10.04        | 1.79±0.19             |

NAC, N-acetylcysteine; CDDP, cisplatin; GSH, glutathione; MDA, malondialdehyde; SOD, superoxide dismutase. Data are expressed as the mean ± SD. *P<0.05, **P<0.01 vs. the negative control.
effects caused by the platinum compound. These findings suggest that NAC may be a useful supplement in chemotherapy involving platinum compounds.

Acknowledgements

This study was supported by funding from the Key Science and Technology Program of Hangzhou (grant no. 20130733Q30).

References

1. Acharya M and Lau-Cam CA: Comparison of the protective actions of N-acetylcysteine, hypotaurine and taurine against acetaminophen-induced hepatotoxicity in the rat. J Biomed Sci 17 (Suppl 1): S35, 2010.
2. Balansky R, Ganchev G, Itcheva M, Steele VE and De Flora SD: Prevention of cigarette smoke-induced lung tumors in mice by budesonide, phenethyl isothiocyanate, and N-acetylcysteine. Int J Cancer 126: 1047-1054, 2010.
3. Baumgardner JN, Shankar K, Hennings L, Albano E, Badger TM and Ronis MJ: N-acetylcysteine attenuates progression of liver pathology in a rat model of nonalcoholic steatohepatitis. J Nutr 138: 1872-1879, 2008.
4. Arftzen DP, Johnson EW, Wilfong ER, Jung AE and Bobb AJ: Distribution of radio-labeled N-acetyl-L-cysteine in Sprague-Dawley rats and its effect on glutathione metabolism following single and repeat dosing by oral gavage. Cutan Ocul Toxicol 26: 113-134, 2007.
5. Aikuri KR, Mantovani JJ, Herenzen LA and Herzenz LA: N-acetylcysteine - a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol 7: 355-359, 2007.
6. Zwingmann C and Bilodeau M: Metabolic insights into the hepatoprotective role of N-acetylcysteine in mouse liver. Hepatology 43: 454-463, 2006.
7. Raitos JE, Whiller S, Chapman BE and Kuchel PW: Kinetics of uptake and deacetylation of N-acetylcysteine by human erythrocytes. Int J Biochem Cell Biol 39: 1698-1706, 2007.
8. Mansour HH, Haefez HF, Fahmy NM and Hanna NF: Protective effect of N-acetylcysteine against radiation induced DNA damage and hepatic toxicity in rats. Biochem. Pharmacol 75: 773-780, 2008.
9. Slim R, Toborek M, Robertson LW, Lehmier HJ and Hennig B: Cellular glutathione status modulates polychlorinated biphenyl-induced stress response and apoptosis in vascular endothelial cells. Toxicol Lett 166: 36-42, 2000.
10. Eastman A: Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 2: 275-280, 1990.
11. van Mooreel CJ, Pincedo HM, Smid K, et al.: Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours. Eur J Cancer 36: 2420-2429, 2000.
12. Kuhad A, Tirkey N, Pilkhwala S and Chopra K: Renoprotective effect of Spirulina fusiformis on cisplatin-induced oxidative stress and renal dysfunction in rats. Renal Failure 28: 247-254, 2006.
13. Clowen NG, Re A, Mchale MT, et al.: Evaluation of D-methionine as a cytoprotectant in cisplatin reoiment of an animal model for ovarian cancer. Anticancer Res 20: 4205-4209, 2000.
14. Dehne N, Lautermann J, Petrat F, et al.: Cisplatin ototoxicity: involvement of iron and enhanced formation of superoxide anion radicals. Toxicol Appl Pharmacol 174: 27-34, 2001.
15. Thomas Dickey D, Muldoon LL, Kraemer DF, et al.: Protection against cisplatin ototoxicity by N-acetylcysteine in a rat model. Hear Res 193: 25-30, 2004.
16. Wang FG and Xi JJ: The influence of acetylcysteine on cytokines of alcoholic liver injury in rat. Chin J Public Health 25: 336-337, 2009 (In Chinese).
17. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
18. Singh NP, McCoy MT, Tice RR and Schneider EL: A simple technique for quantification of low levels of DNA damage in individual cells. Exp Cell Res 175: 184-191, 1988.
19. Zwelling LA, Anderson T and Kohn KW: DNA-protein and DNA interstrand cross-linking by cis- and trans-platinum (II) diamininedichloride in L1210 mouse leukemia cells and relation to cytotoxicity. Cancer Res 39: 365-369, 1979.
20. Blommaert FA, van Dijk-Knijnenburg HC, Dijt FJ, et al.: Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells. Biochemistry 34: 8474-8480, 1995.
21. Serpeloni JM, Barcelos GR, Friedmann Angeli JP, et al.: Dietary carotenoid lutein protects against DNA damage and alterations of the redox status induced by cisplatin in human derived HepG2 cells. Toxicol In Vitro 26: 288-294, 2013.
22. Mistry P, Lee C and McBrien DC: Intracellular metabolites of cisplatin in the rat kidney. Cancer Chemother Pharmacol 24: 73-79, 1989.
23. Chen G, Hutter KJ and Zeller WF: Positive correlation between cellular glutathione and acquired cisplatin resistance in human ovarian cancer cells. Cell Biol Toxicol 11: 273-281, 1995.
24. Godbou JT, Pexavento J, Hartman ME, Manson SR and Freund GG: Methylglyoxal enhances cisplatin-induced cytotoxicity by activating protein kinase Cdelta. J Biol Chem 277: 2554-2561, 2002.
25. YJ Wu, Muldoon LL and Neuwelt EA: The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway. J Pharmacol Exp Ther 312: 424-431, 2005.
26. Chirino YI, Trujillo J, Sánchez-González DJ, et al.: Selective iNOS inhibition reduces renal damage induced by cisplatin. Toxicol Lett 176: 48-57, 2008.
27. Antunes LM, Durin JD and Bianchi MLP: Effects of the antioxidants curcumin and cisplatin-induced nephrotoxicity and lipid peroxidation in rats. Pharmacol Res 43: 145-150, 2001.
28. Cetin R, Devrim E, Kılıçoğlu B, Avci A et al.: Cisplatin impairs antioxidant system and causes oxidation in rat kidney tissues: possible protective roles of natural antioxidant foods. J Appl Toxicol 26: 42-46, 2006.
29. Shan XQ, Aw TY and Jones DP: Glutathione-dependent protection against oxidative injury. Pharmacol Ther 47: 61-71, 1990.
30. Powers SK, Quinidy JC and Kavazis AN: Exercise-induced cardioprotection against myocardial ischemia-reperfusion injury. Free Radic Biol Med 44: 192-201, 2008.
31. Nishino Y, Takemura S, Minamiyama Y, et al.: Targeting superoxide dismutase to renal proximal tubule cells attenuates vancomycin-induced nephrotoxicity in rats. Free Radic Res 37: 731-739, 2003.
32. Oktiem F, Arslan MK, Ozguner F, Candir O, Yilmaz HR et al.: In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced nephrotoxicity: protection by erdosteine. Toxicology 215: 227-233, 2005.
33. Termini J: Hydroperoxide-induced DNA damage and mutations. Mutat Res 450: 107-124, 2000.
34. Lykkefjeldt J: Malondialdehyde as biomarker of oxidative damage to lipids caused by smoking. Clin Chim Acta 380: 50-58, 2007.
35. Mendonça LM, dos Santos GC, dos Santos RA, et al.: Evaluation of curcumin and cisplatin-induced DNA damage in PC12 cells by the alkaline comet assay. Hum Exp Toxicol 29: 635-643, 2010.
36. Francescato HD, Costa RS, Scavone C and Coimbra TM: Parthenolide reduces cisplatin-induced renal damage. Toxicology 230: 64-75, 2007.
37. Gao M, Wu NX, Song Y, Jin LZ, Lou JL and Tao H: PBR153-induced oxidative stress and cell apoptosis on cultured rat Sertoli cells. Toxicol Res 2: 173-179, 2013.